Non-small cell lung cancer therapy in the elderly

Area of Science:

• Geriatric Oncology
• Thoracic Malignancies
• Clinical Trial Design

Background:

• Lung cancer remains a leading cause of cancer mortality globally, disproportionately affecting the elderly.
• An increasing number of older adults are diagnosed with lung cancer, necessitating tailored treatment strategies.
• Elderly patients often present with comorbidities and physiological decline, complicating chemotherapy selection and increasing toxicity risks.

Purpose of the Study:

• To address the challenges in selecting appropriate chemotherapy regimens for elderly lung cancer patients.
• To highlight the importance of comprehensive geriatric assessment in optimizing treatment for older adults with non-small cell lung cancer (NSCLC).
• To review recent therapeutic advancements for elderly NSCLC patients and identify gaps in clinical trial data.

Main Methods:

• Review of current literature and clinical trial data concerning lung cancer treatment in the elderly population.
• Emphasis on the role of comprehensive geriatric assessment (CGA) in treatment selection.
• Discussion of challenges and recommendations for future elderly-specific clinical trials in NSCLC.

Main Results:

• Comprehensive geriatric assessment is a valuable tool for stratifying elderly patients for chemotherapy.
• Few clinical trials have specifically focused on elderly patients with NSCLC, particularly in early stages.
• Current trials rarely incorporate functional status and comorbidity assessments within geriatric evaluations.

Conclusions:

• Effective selection of elderly patients for standard or attenuated chemotherapy requires careful consideration of individual health status.
• Future NSCLC clinical trials must prioritize the inclusion of geriatric assessments and elderly-specific endpoints.
• Further research is needed to evaluate novel targeted therapies and optimize treatment strategies for the growing elderly lung cancer population.